and the Società Italiana della Retina - Home | … ceremony at the elegant nearby sister hotel, the...

P.O. Box 6305, 50 Staniford Street, 7th Floor, Boston, MA 02114 T: 617.227.8767 F: 617.367.4908 [email protected] www.retinasociety.org

Rome, ItalySeptember 21 – 25, 2011

The Retina Society44th AnnuAl Scientific Meeting

and the

Società Italiana della Retina

The joint meeting is being held under the distinguished auspices of:The President of the Italian Republic

The Ministry of Health.The Mayor of the City “Roma Capitale”

44th Annual Retina Society Scientific Session 5

ST. PETER’S BASCILLICA WELCOME

Dear Colleagues, It is our mutual pleasure to welcome you to Rome, the Eternal City, for the Annual Scientific Meeting of the Retina Society in conjunction with the Società Italiana della Retina (SIR), September 21st to 25th, 2011. This year’s meeting, made possible through the close coordination between the Retina Society, the SIR and the Fondazione G.B. Bietti, promises to be a uniquely rewarding experience.

There will be a series of outstanding scientific presentations occurring Wednesday, September 21st through Sunday, September 25th on a wide variety of topics, in addition to a truly unique social program. The setting is the Westin Excelsior, one of the most storied and gracious hotels in the city located centrally on the via Veneto in close proximity to numerous landmarks, including the Spanish Steps, the Villa Borghese, and the American Embassy. Social events include the opening ceremony at the elegant nearby sister hotel, the St. Regis, in addition to a reception at the Campidoglio organized through the kind offices of Mayor Giovanni Alemanno, a gala evening at the Museo Borghese, home to incomparable works of art and gardens, and finally the closing banquet at the Villa Miani. No efforts have been spared to provide an incomparable, educational and social experience for the members and guests.

We hope that you will find this to be a memorable opportunity to learn from your most esteemed colleagues from the United States as well as Europe and around the world, to experience the comradery of our profession in one of the world’s most beautiful as well as architecturally and historically important cities. We look forward to welcoming you in person.

Sincerely,

The Retina Society and the Società Italiana della Retina4

Mark S. Blumenkranz, MD President

The Retina Society

Monica Varano, MD President

Società Italiana della Retina

Mario Stirpe, MD President

IRCCS Fondazione G.B. Bietti

Mark Blumenkranz, Mayor Giovanni Alemanno and Mario Stirpe

44th Annual Retina Society Scientific Session 2323The Retina Society and the Società Italiana della Retina22

PROGRAM-IN-BRIEFCAPITOLINE MUSEUM

WEDNESDAY, SEPTEMBER 21

12:00 Noon Exhibit Set-Up—Ludovisi/Borghese Rooms

12:00 Noon Speaker Ready Room Opens (Room 119)

12:00 – 3:00 pm The Retina Society Executive Committee Meeting

3:00 – 7:00 pm Meeting Registration—Winter Garden Foyer

3:30 – 6:45 pm Interesting Retinal Cases/Video Presentations—Winter Garden

7:00 – 10:00 pm Welcoming Reception—St. Regis Hotel Ritz Ballroom—Shuttle Service

THURSDAY, SEPTEMBER 22

7:00 am Meeting Registration—Winter Garden

Exhibits/Continental Breakfast—Ludovisi/Borghese Rooms

7:00 – 10:00 am Spouses/Guests Hospitality Suite—Trianon Room

7:30 am – 12:30 pm Scientific Session—Winter Garden Room

12:30 – 1:30 pm Scientific Session Meeting Attendees Lunch—Ludiovisi/Borghese Rooms

1:30 – 2:00 pm Poster Viewing and Dessert—Campidoglio/Fori/Pincio Rooms

2:00 – 5:00 pm Scientific Session—Winter Garden

6:00 – 9:00 pm Reception, Piazza del Campidoglio—buses depart Excelsior Hotel beginning at 5:30

FRIDAY, SEPTEMBER 23

7:00 am Registration/Continental Breakfast/Exhibits—Ludovisi/Borghese Rooms

7:00 – 10:00 am Spouses Hospitality Suite—Trianon

7:30 am – 12:05 pm Scientific Session —Winter Garden Room

12:30 – 4:00 pm Vatican Tour—Buses depart Excelsior Hotel 12:30 pm

7:00 – 11:00 pm Dinner/dance, Villa Miani, buses depart Excelsior Hotel 6:30 pm

SATURDAY, SEPTEMBER 23

7:00 am Meeting Registration—Winter Garden

Exhibits/Continental Breakfast—Ludovisi/Borghese

7:00 – 10:00 am Spouses/Guests Hospitality Suite—Trianon Room


11:00 am – 1:00 pm Palazzo Barberini for Accompanying Persons

12:00 – 1:00 pm Annual Business Meeting—Retina Society Members only

7:00 – 11:00 pm Galleria Borghese and Gardens—buses depart Excelsior Hotel at 6:30 pm

SUNDAY, SEPTEMBER 24

7:00 am Continental Breakfast/Exhibits—Ludovisi/Borghese Rooms


ADJOURN

The Retina Society and the Società Italiana della Retina 44th Annual Retina Society Scientific Session30 31

THE J. DONALD GASS AWARD RECIPIENT OF THE J. DONALD GASS AWARD 2011

In 2006, The Retina Society inaugurated the J. Donald M. Gass lectureship. Dr. Gass was a peerless observer of the fundus. His unique and repeated ability to identify fundamental patterns of disease from the mass of seemingly chaotic details invites sincere comparison to Michelangelo working in marble. With this lectureship,

we honor his memory as a warm and cherished member and friend as well as his inestimable importance to our patients and our field.

AWARD SELECTION COMMITTEE:

Donald J. D’Amico, MD, Chair Thomas R. Friberg, MDSteven D. Schwartz, MDCynthia A. Toth, MDGeorge A. Williams, MD

PRIOR RECIPIENTS OF THE AWARD ARE:

2010 Ursula Schmidt-Erfurth MD, Vienna Austria 2009 Philip J. Rosenfeld, MD, Miami, FL 2008 Lawrence A. Yannuzzi, MD, New York, NY 2007 Lee M. Jampol, MD, Chicago, IL 2006 Carmen A. Puliafito, MD, Los Angeles, CA

MARIO STIRPE, MD

Dr. Mario Stirpe is one of the most noted and accomplished retinal surgeons in the world. He has made many important contributions and unique observations in the diagnosis and treatment of retinal disease,

and is the 2011 recipient of the Retina Society's J. Donald M. Gass Award.Immediately following his graduation from medical school and presentation

of his thesis in Rome, he entered training in Ophthalmology under Professor Gian Battista Bietti. Professor Bietti was a towering figure in Ophthalmology and was interested in every aspect of our specialty; his name is commemorated in numerous disease observations, surgical procedures, and prestigious awards and medals. Undoubtedly recognizing the potential in the young Dr. Stirpe to

become his greatest student and successor, Dr. Stirpe was encouraged, on completion of his residency in 1963, to work with Professor Stallard in London and acquire training in the treatment of ocular tumors and, in particular, retinoblastoma. Dr. Stirpe returned to Rome bringing the very latest cobalt plaque techniques with him, and, for the next five years, was intensively involved in the treatment of ocular tumors. In this highly active period he published no less than 22 papers, including important observations on the effects of radiation on orbital development, while developing an extremely busy clinical and surgical practice. These remarkable efforts led to his being named Professor of Ophthalmology at the University of Rome just five years after completing his residency.

His career then turned toward the disease that continues to fascinate him to this day—myopia—and he dedicated himself to developing a new surgical treatment for retinal detachment with macular holes, a condition that is surprisingly common in Italy and for which there was no effective treatment. The procedure he devised was an innovative adaptation of scleral buckling to the posterior pole which resulted in greatly improved results and which he continues to use most effectively today. Despite the apparent ease today of repairing these detachments with vitrectomy (in which he and his group are also most skilled), recent publications by others have confirmed his results documenting better visual acuity outcomes following posterior buckling as compared to vitrectomy. The procedure requires extreme surgical skill and is a testament to Dr. Stirpe’s passion to improve the situation for patients afflicted with high myopia. He has made many other contributions in myopia, including characterizing particular risks of cataract surgery, documenting unusual aspects in myopic giant retinal tears, and reporting new observations on myopic macular abnormalities, as well as sponsoring important meetings and monographs on this disease. Indeed, he is one of the world’s most experienced and prolific retinal specialists in regard to high myopia and its many difficult complications.

Dr. Stirpe’s intensive work with detachment and surgical retina led to his being named Retina Service Director at the University of Rome. Although he experimented with open sky vitrectomy, he immediately recognized the revolution in progress with Robert Machemer’s pars plana approach, and he travelled frequently to Miami becoming one of the very first Europeans to have modern vitrectomy skills, making strong ties with Drs. Norton, Gass, Machemer, Michels, and many other luminaries in our field.

After the death of Dr. Bietti in 1977, Dr. Stirpe began formulating plans to continue Dr. Bietti's important legacy. While continuing to organize regional and international congresses on important retinal themes, in 1982, he created

Continues on next page

The Retina Society and the Società Italiana della Retina32 44th Annual Scientific Session 33

RECIPIENT OF THE J. DONALD GASS AWARD

Continued from previous page

the Fondazione Bietti which has become one of the most influential foundations in Ophthalmology. The Fondazione is a remarkable incubator of talent. Under Dr. Stirpe’s leadership, many of the individuals in his group have achieved their own fame and recognition; as an example, very few centers can boast a greater number of Club Jules Gonin members within a single organization. The Fondazione continues to expand in size, scope, and location, and in 2005 was designated by the Italian Health Ministry as an “Institution for Hospitalization and Care with Scientific Characteristics in the Field of Ophthalmology” in a unique recognition of its excellence. It is also anotably active sponsor of meetings and publishes many peer-reviewed studies, books, and monographs.

Although his many scientific accomplishments and tireless efforts would be remarkable as defining features for most individuals, Dr. Stirpe is also most deservedly renowned for his kindness and generosity as a host and friend. He is unquestionably the most charming and elegantly attired ophthalmologist that we will ever know. To be with Dr. Stirpe “al tuo fianco” in Rome is to experience the real splendor of his magnificent city. He is utterly passion-ate about everything Roman, from walking its maze of streets, kayaking its waters, and describing its infinitely diverse pasta varieties, to sitting down in a favorite restaurant (Dal Bolognese and Al Moro are essentially part of his home) with family and friends. He is also completely dedicated to his lovely wife Marisa who is vivacious and fashionable in the most wonderful Italian way. Together, they have most generously shared their many gifts with all of us, and have made the world of retina—and all of us--that much more Italian. For his accomplishments in high myopia, for his creation and continued leadership of the Fondazione Bietti, and for his endless kindness as a colleague and friend, the Retina Society is extremely honored to present the 2011 J. Donald. M. Gass Award to Dr. Mario Stirpe.

Donald J. D’Amico, MD

PIAZZA NAVONA

44th Annual Retina Society Scientific Session 43The Retina Society and the Società Italiana della Retina42 43

FONTANA DI TREVI (TREVI FOUNTAIN) SCIENTIFIC PROGRAM — THURSDAY

TH

UR

SD

AY

, S

EP

TE

MB

ER

2

2

THURSDAY, SEPTEMBER 22

7:00 am REGISTRATION/CONTINENTAL BREAKFAST/EXHIBITS 7:30 WELCOME Mark S. Blumenkranz, MD, Chair, Program, President, The Retina Society Mario Stirpe, MD, Co-Chairman, Program, President, IRCCS Fondazione G.B. Bietti Monica Varano, MD, President, Società Italiana della Retina

SESSION 1 — RETINAL PHARMACOLOGY: VEGF INHIBITION Presiding Officer: Mark S. Blumenkranz, MD Moderator: Rosario Brancato, MD

7:30 am Intravitreal Ranibizumab for Vascularized Pigment Epithelium Detachment Francesco Bandello, MD

7:37 Questions

7:40 High (2.0 MG) versus Conventional-dose (0.5 MG) Ranibizumab for Managing Vascularized Pigment Epithelial Detachments Associated with Age-related Macular Degeneration

Clement K. Chan, MD 7:47 Questions

7:50 Effects of Intravitreal Anti-VEGF Agents on Retinal Morphology, Neovascular Network Size and Best Corrected Visual Acuity in Patients with Pigment Epithelium Detachment due to Occult Choroidal Neovascularization

Daniele Veritti, MD 7:57 Questions

8:00 Correlation of Retinal Morphology and Function Under Anti-VEGF Therapy In Patients with Neovasular Age-related Macular Degeneration (nAMD)

Ursula Schmidt-Erfurth, MD 8:07 Questions

8:10 Long-term Results of Anti-VEGF Therapy for Choroidal Neovascularization Associated with Age-related Macular Degeneration

John T. Thompson, MD 8:17 Questions

8:20 Intravitreal Ranibizumab versus Bevacizumab in Choroidal Neovascularization in Pathologic Myopia. A Randomized Study

Alfredo Pece, MD 8:27 Questions

8:30 Impact of Availability of Anti-VEGF Therapy on Vision Impairment and Blindness due to Neovascular Age-related Macular Degeneration

Susan B. Bressler, MD 8:37 Questions

8:40 Combined Anti-VEGF and Photodynamic Therapy for Treatment of Age-related Macular Degeneration Refractory to Anti-VEGF Monotherapy

Lawrence P. Chong, MD 8:47 Questions


8:50 am Combined Therapy (ICombined Therapy Intravitreal Bevacizumab Plus Verteporfin Photodynamic Therapy) versus Intravitreal Bevacizumab Monotherapy for Choroidal Neovascularization Due to Age-related Macular Degeneration. A One-year Follow-up Study

Sandro Saviano, MD 8:57 Questions

9:00 Dexamethasone Intravitreal Implant Alone and as an Adjunct to Ranibizumab for Treatment of Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Michael A. Singer, MD 9:07 Questions

9:10 Angiographic Findings Following X-ray Irradiation for Treatment of Wet Age-related Macular Degeneration: 18 Month Follow-up

Darius M. Moshfeghi, MD 9:17 Questions

9:20 VEGF Trap-Eye Vs Ranibizumab for Neovascular Age-related Macular Degeneration: Results From 2457 Patients in the Phase 3 VIEW 1 and VIEW 2 Studies

Jeffrey S. Heier, MD 9:27 Questions

9:30 Asymptomatic Fluid in the Second Eye of Patients with Neovascular Age-related Macular Degeneration: Detection by Optical Coherence Tomography and Treatment with Anti-VEGF Therapy

Lucian V. Del Priore, MD, PhD 9:37 Questions

9:40 REFRESHMENT BREAK/EXHIBITS

SESSION 2 — TREATMENT OF MACULAR EDEMA Presiding Officer: Julia A. Haller, MD Moderator: David Boyer, MD

10:10 VEGF Trap-Eye in Diabetic Macular Edema: One-year Results of the DA VINCI Study W. Lloyd Clark, MD 10:17 Questions

10:20 Ranibizumab (Anti-VEGF) for Vision Loss Due to Diabetic Macular Edema Results of Two Phase III Randomized Trials

Anthony P. Adamis, MD 10:27 Questions

10:30 Rationale of Diabetic Retinopathy Clinical Research Network Intravitreal Anti-VEGF Treatment and Follow-up of Center-involved Diabetic Macular Edema

Lloyd Paul Aiello, MD, PhD 10:37 Questions

10:40 Vision-related Function after Ranibizumab Treatment for Diabetic Macula Edema (DME) by Better- or Worse-Seeing Eyes: Clinical Trial Results from RESTORE, RIDE, and RISE

Neil M. Bressler, MD 10:47 Questions

10:50 am To Estimate the Potential Costs and Savings Associated with Intravitreal Ranibizumab with Prompt or Deferred Focal/Grid Laser as Compared with Prompt Focal/Grid Laser for Diabetic Macular Edema (DME)

Scott M. Friedman, MD 10:57 Questions

11:00 Effects of Ranibizumab on Reading Speed Through 24 Months in Patientswith Vision Impairment from Diabetic Macular Edema (DME)

Ivan J. Suner, MD 11:07 Questions

11:10 VEGF Trap-Eye in CRVO: Results from the Phase 3 OPERNICUS Study David S. Boyer, MD 11:17 Questions

11:20 Dexamethasone Intravitreal Implant Rapidly Improves Best-Corrected Visual Acuity within 7 Days in Patients with Retinal Vein Occlusion

Julia A. Haller, MD 11:27 Questions

11:30 Patients with Macular Edema Due to Branch Retinal Vein Occlusion Achieve Greater Clinical Benefit from Dexamethasone Intravitreal Implant When Treated Within the First 90 Days Early Following Onset of Macular Edema

Baruch D. Kuppermann, MD, PhD 11:37 Questions

11:40 Combination Therapy for Diffuse Diabetic Macula Edema (DME) Keith A. Warren, MD 11:47 Questions

11:50 Functional and Anatomical Response of Idiopathic Macular Telangiectasis to Intravitreal Anti-VEGF Treatment with Bevacizumab

Shlomit Schaal MD 11:57 Questions

12:00 pm Efficacy and Safety Results of Participants Receiving ILUVIEN (Fluocinolone Acetonide) Insert in the FAME Program

Rajendra S. Apte, MD, PhD 12:07 Questions

12:10 Clinical Correlation of Wide-angle Fluorescein Angiography and Retinal Oxymetry Findings in the Treatment Response of Retinal Vein Occlusions

Veronica A. Kon-Jara, MD 12:17 Questions

12:20 Peripheral Polypoidal Choroidal Vasculopathy: A Report of 10 Eyes Darin Goldman, MD 12:27 Questions

12:30 – 1:30 LUNCH — Ludovisi/Borghese Rooms

1:30 – 2:00 POSTER VIEWING — Campidoglio/Fori/Pincio Rooms

TH

UR

SD

AY

, S

EP

TE

MB

ER

2

2T

HU

RS

DA

Y, S

EP

TE

MB

ER

2

2

SCIENTIFIC PROGRAM — THURSDAYSCIENTIFIC PROGRAM — THURSDAY


SESSION 3 — RETINAL RESEARCH: THE BENCH Presiding Officer: William F. Mieler, MD Moderator: Claudio Azzolini, MD

2:00 pm Photoreceptor Regeneration in a Swine Model of Retinal Damage Henry J. Kaplan, MD 2:07 Questions

2:10 Long-term Suppression of Ocular Neovascularization with a Single Intravitreal Administration of a Viral Gene Transfer Vector Coding for Bevacizumab

Szilard Kiss, MD 2:17 Questions

2:20 Clinicopathologic Features of Epiretinal Proliferation in Familial Exudative Vitreoretinopathy Sander R. Dubovy, MD 2:27 Questions

2:30 Mechanism of Cell Loss in Age-related Macular Degeneration and Retinal Degenerations. A Path to Clinical Trials in Neuroprotection

Demetrios Vavvas MD 2:37 Questions

2:40 Role of Fas Signaling in the Retina after Sodium Iodate Mediated Retinal Pigment Epithelium Injury

David N. Zacks, MD, PhD 2:47 Questions

2:50 From Muller Glia Cells to Photoreceptors Claudio Azzolini, MD 2:57 Questions

3:00 PLGA Nanospheres Encapsulated within Thermo-responsive Hydrogel for Ocular Delivery of Dexamethasone Sodium Phosphate

William F. Mieler, MD 3:07 Questions

3:10 Constellation 2.0: Eliminating Infusion Bubbles and Uncontrolled Reflux Stephen R. Russell, MD 3:17 Questions

3:20 A Cat Model for Chronic Suprachoroidal Electrical Stimulation of the Retina Penelope J. Allen, FRANZCO 3:27 Questions

SESSION 4 — CLINICAL RESEARCH: THE BEDSIDE Presiding Officer: Allen C. Ho, MD Moderator: Steven D. Schwartz, MD

3:30 pm Ocriplasmin for the Treatment of Symptomatic Vitreomacular Adhesions (sVMA): Results from the MIVI-TRUST Phase III program

Allen C. Ho, MD 3:37 Questions

3:40 Ocriplasmin for the Treatment of Macular Holes:Results from the MIVI-TRUST Phase III Program

Peter K. Kaiser, MD 3:47 Questions

3:50 Preclinical Rationale and Phase 1 Safety Trial Design for Stem Cell Derived Retinal Pigment Epithelium Therapy for the Treatment of Stargardt and Age-related Macular Degenerations

Steven D. Schwartz, MD 3:57 Questions

4:00 Phase I Human Safety Study of Integrin Antagonist in Diabetic Retinopathy Subjects Hugo Quiroz-Mercado, MD 4:07 Questions

4:10 Oral Synthetic cis-Retinoid Therapy in Subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) due to Lecithin:Retinol Acyltransferase (LRAT) or Retinal Pigment Epithelial 65 Protein (RPE65) Mutations: Preliminary Results of a Phase Ib Open Label Trial

David A. Saperstein, MD 4:17 Questions

4:20 Randomized, Double-masked, Controlled Translational Investigation of Bevacizumab for Severe Retinal Detachment Due to Proliferative Diabetic Retinopathy: 3 Month Results

Elliott Sohn, MD 4:27 Questions

4:30 Effects of Music Therapy on Patients’ Anxiety During Intravitreal Injections: A Randomized Clinical Trial

Ron Adelman, MD 4:37 Questions

4:40 Cytokine Concentration in Aqueous Humor of Eyes with Diabetic Macular Edema Jost B. Jonas, MD 4:47 Questions

4:50 Novel Methods to Enhance Reading Ability in Patients with Macular Disease Daniel B. Roth, MD 4:57 Questions

5:00 ADJOURN

TH

UR

SD

AY

, S

EP

TE

MB

ER

2

2T

HU

RS

DA

Y, S

EP

TE

MB

ER

2

2

SCIENTIFIC PROGRAM — THURSDAYSCIENTIFIC PROGRAM — THURSDAY


SCIENTIFIC PROGRAM — FRIDAYSCIENTIFIC PROGRAM — FRIDAY

FRIDAY, SEPTEMBER 23

7:00 am REGISTRATION/CONTINENTAL BREAKFAST/EXHIBITS

SESSION 5 — SURGICAL TECHNIQUES Presiding Officer: Mark W. Johnson, MD Moderator: Donald J. D’Amico, MD

7:30 Outcomes of Small Incision Vitreoretinal Surgery without Trimming of Vitreous Base for Rhegmatogenous Retinal Detachment

Homayoun Tabandeh, MD, MS 7:37 Questions

7:40 Minimalist Pars Plana Vitrectomy for Repair of Primary Rhegmatogenous Retinal Detachment Mark W. Johnson, MD 7:47 Questions

7:50 Pars Plana Vitrectomy Alone after Primary Pseudophakic Macula-off Rhegmatogenous Retinal Detachment

Vicente Martinez-Castillo, MD 7:57 Questions

8:00 Continuous Indirect Ophthalmoscope Monitored Drainage of Subretinal Fluid Edwin H. Ryan,MD 8:07 Questions

8:10 Tamponade Volume, Posterior Pressure, and Trabecular Block in Silicone-Oil-Associated Glaucoma

Hermann D. Schubert, MD 8:17 Questions

8:20 Sequential Epiretinal Membrane Removal: Internal Limiting Membrane Pattern Constantin J. Pournaras, MD 8:27 Questions

8:30 Intraoperative Ocular Coherence Tomography: Macular Morphology following Posterior Vitreous Separation, ERM and ILM Peeling

Antonio P. Ciardella, MD 8:37 Questions

8:40 Intrasurgical Spectral Domain Optical Coherence Tomography—An Update Susanne Binder, MD 9:47 Questions

8:50 Trypan Blue versus Brilliant Blue G in Epiretinal Membrane Surgery Christiane I. Falkner-Radler, MD 8:57 Questions

9:00 The Gold Standard of Secondary Intraocular Lens Implantation in the Transconjunctival Era Cesare Forlini, MD 9:07 Questions

9:10 Vitrectomy and Gas Tamponade with Internal Limiting Membrane Peeling for Myopic Foveoschisis

Settimio Rossi, MD

9:17 Questions

9:20 am The IRISS Ocular Robotic Surgical Platform Jean-Pierre Hubschman, MD 9:77 Questions

9:30 Polyethylene Glycol (PEG) Hydrogel Polymer Sealant for Sclerotomy Closure: Preliminary in vivo Clinical Results

Fabio Patelli, MD 9:37 Questions

9:40 Coloring of PFCL Facilitates Safe and Efficient Removal of Temporary Tamponades Stanislao Rizzo, MD 9:47 Questions

9:50 Evolving Techniques for Silicone Oil Injection, Removal, and Reoperation for Epimacular Membrane (EMM) or Proliferative Vitreoretinopathy (PVR) without Oil Removal

Steve Charles, MD 9:57 Questions

10:00 Use of HeavySIL 1500, a New Heavier-than-water Endotamponade, in Complicated Retinal Detachment Surgery

Cesare Mariotti, MD 10:07 Questions

10:10 Presence of Residual Perfluorocarbon Liquid and Its Interaction with Heavy Silicone Oil: Risk Factor for Sticky Oil Formation

Mario R. Romano, MD, PhD 10:17 Questions


SESSION 6 — AWARD PRESENTATIONS

10:50 – 10:55 Introduction of Michael F. Marmor, MD by Mark S. Blumenkranz, MD RETINA RESEARCH AWARD OF MERIT — CHARLES L. SCHEPENS LECTURE

10:55 – 11:15 The Art of Retina Michael F. Marmor, MD

11:15 – 11:20 Introduction of Mario Stirpe by Donald J. D’Amico MD 5th ANNUAL J. DONALD M. GASS AWARD

11:20 – 11:40 Posterior Staphyloma in High Myopic Eyes: Vitreoretinal Pathology Mario Stirpe, MD

11:40 – 11:45 Introduction of Fellowship Awards by William F. Mieler, MD 11:45 FELLOWSHIP RESEARCH AWARD PRESENTATION ERK-mediated Activation of Fas Apoptosis Inhibitory Molecule (Faim2) Cagri G. Besirli, MD

11:55 RAYMOND R. MARGHERIO AWARD PRESENTATION A Novel Strategy to Develop Preventative Therapy for Proliferative Vitreoretinopathy Marc-Andre Rheaume, MD

12:05 pm ADJOURN

FR

ID

AY

, S

EP

TE

MB

ER

2

3F

RID

AY

, S

EP

TE

MB

ER

2

3


SATURDAY, SEPTEMBER 24


SESSION 7 — TUMORS Presiding Officer: Timothy G. Murray, MD, MBA Moderator: Evangelos S. Gragoudas, MD

7:30 Combined Simultaneous Transpupillary Hyperthermia ICG-assisted Photodynamic Therapy (CSTIP) with Intravitreal Ranibizumab for Small

Peter E. Liggett, MD 7:37 Questions

7:40 Prognostic Significance of Gene Expression Profile Class of Posterior Uveal Melanomas in Prospective Single Center Study

James J. Augsburger, MD 7:47 Questions

7:50 Paraneoplastic Bilateral Diffuse Uveal Melanocytic Proliferation is Caused by a Factor Found in the IgG Fraction of Serum

Jose S. Pulido, MD 7:57 Questions

8:00 Optic Nerve Damage after Irradiation of Introcular Tumors Evangelos S. Gragoudas 8:07 Questions

8:10 Hemodynamic Modifications of the Retina and Choroïd following Proton Beam Irradiation of Uveal Melanomas. Panoramic Fluorescein Angiography and ICG Study

Leonidas Zografos, MD 8:17 Questions

8:20 Proton Beam Radiation of Choroidal Hemangioma Michael H. Foerster, MD, PhD 8:27 Questions

8:30 Intrarterial Chemotherapy for Retinoblastoma Using Routes other than the Ophthalmic Artery David H. Abramson, MD 8:37 Questions

8:40 Intra-arterial Chemotherapeutic Dosing Strategy Directly Impacts Retinoblastoma Tumor Control

Timothy G. Murray, MD, MBA 8:47 Questions

SESSION 8 — UVEITIS Presiding Officer: Bernard H. Doft, MD Moderator: Douglas A. Jabs, MD

8:50 am Prophylaxis for Endophthalmitis Associated with Intravitreal Injection: Antisepsis and Antibiotics

Harry W. Flynn, Jr., MD 8:57 Questions

9:00 Indolent Nonprogressive Multifocal Choroidal Lesions Lee M. Jampol, MD 9:07 Questions

9:10 Standardization of Uveitis Nomenclature: An Informatics Approach to Classification Criteria Development

Douglas A. Jabs, MD 9:17 Questions

9:20 Cauterization of Leaking Sclerotomies after 23-gauge Transconjunctival Pars Plana Vitrectomy Francesco Boscia, MD 9:27 Questions


SESSION 9 — PEDIATRIC RETINAL DISEASES AND IMAGING Presiding Officer: Michael T. Trese, MD Moderator: Edoardo Midena, MD, PhD

10:00 Evaluation of Plus Disease Progression Using Digital Registration of Multiple Images Jane Myung, MD 10:07 Questions

10:10 Coats’ Disease: Unilateral or Bilateral? Audina M. Berrocal, MD 10:17 Questions

10:20 Angiogenesis and Angiomaintenance in Pediatric Retinal Disease Michael T. Trese, MD 10:27 Questions

10:30 Rescued Vascularization by Norrin in a Model of Retinopathy Kimberly A. Drenser, MD, PhD 10:37 Questions

10:40 Release and Velocity of Micronized Dexamethasone Intravitreal Implants with an Intravitreal Drug Delivery System—Kinematic Analysis with a High-speed Camera

Carsten H. Meyer, MD 10:47 Questions

10:50 Novel Wide-field Montage Spectral-domain Optical Coherence Tomography Technique in Patients with X-linked Retinoschisis

Ninel Z. Gregori, MD 10:57 Questions

SA

TU

RD

AY

, S

EP

TE

MB

ER

2

4S

AT

UR

DA

Y, S

EP

TE

MB

ER

2

4

SCIENTIFIC PROGRAM — SATURDAYSCIENTIFIC PROGRAM — SATURDAY


11:00 am Grading the Severity of Posterior Staphyloma using SD OCT Imaging and Correlation with Macular Complications Including Macular Schisis and Macular Hole Formation

David Sarraf, MD 11:07 Questions

11:10 SD-OCT and HD-MRI Study of Dome-shaped Macula in Pathologic Myopia Giampaolo Amato, MD 11:17 Questions

11:20 Refractive State, Axial Length, and Choroidal Thickness in Central Serous Chorioretinopathy Gaetano R. Barile, MD 11:27 Questions

11:30 Diabetic Retinopathy Viewed as a Neurodegenerative Disorders: In vivo Retinal Glial Cells Activation

Edoardo Midena, MD, PhD 11:37 Questions

11:40 Peripheral Autofluorescence Findings in Age-related Macular Degeneration SriniVas R. Sadda, MD 11:47 Questions

11:50 Line Scanning Angiography for Detection of Retinal and Choroidal Disease Deeba Husain, MD 11:57 Questions

12:00 pm ANNUAL BUSINESS MEETING —THE RETINA SOCIETY

1:00 ADJOURN

SU

ND

AY

, S

EP

TE

MB

ER

2

5SA

TU

RD

AY

, S

EP

TE

MB

ER

2

4

SCIENTIFIC PROGRAM — SUNDAYSCIENTIFIC PROGRAM — SATURDAY

SUNDAY, SEPTEMBER 25


SESSION 10 — IMAGING AND LASERS Presiding Officer: Thomas R. Friberg, MD Moderator: Guido Ripandelli, MD

7:30 am Three-Dimensional High-Definition Live Vitreoretinal Surgery Transmission Using Conventional Telecommunication Lines

Akitoshi Yoshida, MD, PhD 7:37 Questions

7:40 Incorporation of Telemedicine Diabetic Retinopathy Assessment with a Medicare Quality Improvement Program

Ingrid E. Zimmer-Galler, MD 7:47 Questions

7:50 Ophthalmicedge.org (Free Ophthalmic Instructional Website): Current Analytics and Phase II Expansion

Yale L. Fisher, MD 7:57 Questions

8:00 Selective VEGF 165 Blockade can Reverse Retinal Capillary Non-perfusion as Demonstrated on Ultra-wide Angle Angiography

Thomas R. Friberg, MD 8:07 Questions

8:10 Assessment of Retinal Non-Perfusion by Calculating an Ischemic Index in Diabetic Retinopathy and Vein Occlusions with Ultra Wide Field Fluorescein Angiography

Valentina Franco-Cardenas, MD 8:17 Questions

8:20 Multi-imaging Characteristics of Diabetic Macular Edema Stela Vujosevic, MD 8:27 Questions

8:30 Fundus Autofluorescence and Microperimetry in Progressing Geographic Atrophy Secondary to Age-related Macular Degeneration

Elisabetta Pilotto, MD 8:37 Questions

8:40 577 nm Yellow Selective Subthreshold Laser Photocoagulation for the Treatment of Central Serous Chorioretinopathy with Foveal Leakage

Jose A. Cardillo, MD 8:47 Questions

8:50 Subthreshold Micropulse Yellow Laser (577nm) Photocoagulation for Macular Edema (ME) Oh Woong Kwon, MD 8:57 Question

9:00 New Opportunities for Targeted Retina Therapy Using Navigated Laser Giovanni Staurenghi, MD 9:07 Questions


9:10 am Retinal Navigated Laser (Navilas®) Compared Versus Conventional Laser in Diabetic Macular Edema

Anselm Kampik, FEBO 9:17 Questions

9:20 Association between the Efficacy of Half-dose Photodynamic Therapy with Indocyanine Green Angiography and Optical Coherence Tomography Findings in the Treatment of Central Serous Chorioretinopathy

Massimo Nicolo, MD 9:27 Questions


SESSION 11— MACULAR DISEASE – CLINICAL RESEARCH Presiding Officer: Charles C. Barr, MD Moderator: Francesco Bandello, MD

10:00 Genotype-Phenotype Correlations Age-related Macular Degeneration James C. Folk, MD 10:07 Questions

10:10 Genetic Risk Factors for Age-related Macular Degeneration (AMD) Can also be Predictive for the Functional and Anatomical Outcome of Intravitreal Anti-VEGF Treatment

Tongalp H. Tezel, MD 10:17 Questions

10:20 A Genetic Risk Index Correlated with the Choroidal Neovascularization Phenotypes as a Predictive Factor for Neovascular Age-related Macular Degeneration Management

Stephano Piermarocchi, MD 10:27 Questions

10:30 Systems Biology Based Analysis Implicates a Role for Vitamin D Metabolism in the Pathogenesis of Age-related Macular Degeneration

Ivana K. Kim, MD 10:37 Questions

10:40 Retinal Changes Before the Development of Retinal Angiomatous Proliferation Ferdinando Bottoni, MD 10:47 Questions

10:50 Subretinal t-PA with Pneumatic Displacement With and Without Intravitreal Anti-VEGF Agents for the Treatment of Thick Subretinal Hemorrhage Due to Exudative Age-related Macular Degeneration

Sunir J. Garg, MD 10:57 Questions

11:00 Visual Acuity and Retinal Thickness Changes after Pars Plana Vitrectomy for Idiopathic Epiretinal Membranes

Charles C. Barr, MD 11:07 Questions

11:10 am Association of the Preoperative Photoreceptor Layer Defect as Assessed by Optical Coherence Tomography with the Functional Outcome after Macular Hole Closure. A Long Follow-up Study

Panagiotis G. Theodosiadis, MD 11:17 Questions

11:20 Lamellar Macular Holes: Functional and Morphological Retinal Changes Mariacristina Parravano, MD 11:27 Questions

11:30 Posterior Juxtascleral Injection of a Commercially Available Triamcinolone Acetonide Injectable Suspension Plus a Viscoelastic Agent in Refractory Diabetic Macular Edema

Paolo Lanzetta, MD 11:37 Questions

11:40 Incidence of Macular Edema in the Multiple Sclerosis Clinical Program of Fingolimod (FTY720)

Marco A. Zarbin, MD, PhD 11:47 Questions

11:50 DARPin® MP0112 Shows Extended VEGF Inhibition Effect in Diabetic Macular Edema Brian B. Berger, MD 11:57 Questions

12:00 pm Maculopexy (MX) Resolves Diffuse Diabetic Macular Edema Robert E. Morris, MD 12:07 Questions

12:10 Spectral Domain Optical Coherence Tomography and Microperimetry Outcomes after 23 Gauge Vitrectomy for Idiopathic Macular Pucker

Fabo Scarinici, MD 12:17 Questions

12:20 ADJOURN

SCIENTIFIC PROGRAM — SUNDAYSCIENTIFIC PROGRAM — SUNDAY

SU

ND

AY

, S

EP

TE

MB

ER

2

5S

UN

DA

Y, S

EP

TE

MB

ER

2

5


POSTER PROGRAM — ROME, 2011POSTER PROGRAM — ROME, 2011

SALA PINCIO 1 Anita Agarwal, MD Lesion Characteristics in Familial Age-related Macular Degeneration

2 J. Fernando Arevalo, MD Combined Inhibition of Tumor Necrosis Factor (TNF) and Vascular Endothelial Growth Factor (VEGF) for

the Treatment of Macular Edema of Varied Etiologies: A Pilot Study

3 Claudia Bruè, MD Treatment of Macular Edema in Vein Occlusion

4 Antonio M. Casella, MD Correlation Between Spectral Domain—Optical Coherence Tomography and Diffuse Unilateral

Subacute Neuroretinitis

5 Nauman A. Chaudhry, MD Cataract Surgery Outcomes in Eyes with Neovascular Age-related Macular Degeneration Being

Treated with Anti-VEGF Therapy

6 Cynthia Azeredo Cordeiro, MD Toxoplasma Strain-specific Virulence and Modulation of Host Immune Signaling Pathways

7 Eduardo Cunha de Souza, MD Presumed Toxocariasis Presenting as Punctate Inner Choroidopathy (PIC), Idiopathic Choroidal

Neovascularizatio (ICN) and Diffuse Unilateral Subacute Neuroretinitis (DUSN)

8 Susan G. Elner, MD Retinal Metabolic Analysis Utilizing Flavoprotein Fluorescence: A Translational Tool

9 Vincenzo Ferrara, MD The Vitreous Gel as Cause of Failure in Macular Hole Surgery

10 Michael H. Goldbaum, MD Method to Curve Vitrectomy Cutter and Instruments Intraoperatively

11 W. Rex Hawkins, MD Is the Wilmer Institute’s 2009 Age-related Macular Degeneration/Cataract Surgery

Report Credible?

12 Daniel F. Kiernan, MD Intravitreal Triamcinolone Treatment for Brachytherapy-associated Retinopathy Recalcitrant to

Intravitreal Bevacizumab

SALA FORI 13 Hyung-Woo Kwak, MD Two-year Results of Photodynamic Therapy Combined with Intravitreal Anti-Vascular Endothelial

Growth Factor for Polypoidal Choroidal Vasculopathy

14 Marcio Nehemy, MD, PhD CFH, LOC387715 and VEGF Genotypes and the Short-term Response to Antiangiogenic Therapy in

Exudative Age-related Macular Degeneration

15 Julian J. Nussbaum, MD Decreased Expression of Endogenous Antioxidant Enzymes in the Human Diabetic Retina

16 Michael D. Ober, MD The Duration of Activity of Centrifuge Concentrated Intravitreal Triamcinolone

17 R. Joseph Olk, MD Does Oral Zeazanthin Improve the Anatomic and Visual Outcome of Triple Therapy for Subfoveal

Choroidal Neovascularization (CNV) in Age-related Macular Degeneration (ARMD)?

18 Susanna S. Park, MD, PhD Ranibizumab Combined with Proton Beam Irradiation as Treatment for Exudative Age-related Macular

Degeneration: 3 year Follow-up of Pilot Study

19 Firas M. Rahhal, MD Travel to High Mountain Elevations Following Vitrectomy with Gas: A Large Consecutive Case Series

20 Vincent S. Reppucci, MD Scleral Buckle: Why is It Being Ignored?

SALA CAMPIDOGLIO 21 Christopher D. Riemann, MD Early Experience with Intraoperative Intravitreal Methotrexate Infusion During Vitrectomy—Is There a

Role in the Prevention of Proliferative Vitreoretinopathy?

22 Alvaro Rodriguez, MD Photodynamic Therapy and Lamellar Macular Holes in Exudative Age Related Macular Degeneration

23 Julie M. Rosenthal, MD Half-dose and Half-fluence PDT in Central Serous Chorioretinopathy

24 Tommaso Rossi, MD The Pathogenesis of Retinal Damage in Blunt Eye Trauma: Finite Element Modeling

25 Güngör Sobaci, MD The Effect of Combined Bevacizumab and Triamcinolone for Diffuse Diabetic Macular Edema

Refractory to Previous Intravitreal Injections

26 Michael W. Stewart, MD What are the intraocular Half-lives of Ranibizumab and VEGF Trap in Humans: A Mathematical Model

27 William S. Tasman, MD Cataracts in Adult Patients with Retinopathy of Prematurity (ROP)

28 Martin Bruce Wax, MD PanOptica 90806: A Novel Topical Agent for the Treatment of Wet Age-related Macular Degeneration

29 Lihteh Wu, MD Intravitreal TNF-Alpha Inhibitors for Refractory Neovascular Age-related Macular Degeneration: A Pilot Study from the Pan American Collaborative Retina Study (PACORES) Group

30 Gloria Wu, MD Serum Lipids and Retinal Function in Diabetic Patients

31 Seung-Young Yu, MD, PhD Segmentation Error and Macular Thickness Measurements Obtained with Spectral Domain Optical

Coherence Tomography Devices in Neovascular Age-related Macular Degeneration

POSTER # POSTER #

and the Società Italiana della Retina - Home | … ceremony at the elegant nearby sister hotel, the...

Documents

Transcript of and the Società Italiana della Retina - Home | … ceremony at the elegant nearby sister hotel, the...